Side-by-side · Research reference
MOTS-cvsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/68 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
MOTS-c
Vilon
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Immune cell differentiation pathways, chromatin modification
Pathway
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Unknown — no HPA/HPG axis data
Origin
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
MOTS-c
Vilon
Standard dose
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Frequency
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Unknown — literature does not specify chronic administration protocols
Lower / starter dose
2.5–5 mg / week
Recommended due to limited human data.
—
Evidence basis
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Mouse / in vitro only
Duration
4–12 weeks (experimental)
Optimal cycle length unknown.
Not characterised in humans
Reconstitution
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
—
Timing
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
—
Half-life
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
Not published — dipeptides typically <10 min plasma t½
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Route
—
Likely SQ or oral (Khavinson school uses both); no published ROA validation
03Metabolic / Fat Loss Evidence
Parameter
MOTS-c
Vilon
Primary fat target
Diet-induced / metabolic obesity; systemic fat utilization
—
Quantified reduction
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
—
IGF-1 impact
No direct IGF-1 pathway; AMPK-mediated
—
Effect on lean mass
High dose significantly ↑ lean mass in mice
—
Triglycerides
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
—
Effect reversibility
Unknown — no long-term follow-up data
—
Key publication
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
—
04Side Effects & Safety
Parameter
MOTS-c
Vilon
Injection site reaction
Mild irritation (reported)
—
Fluid retention / Edema
Not reported
—
Cardiovascular
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
—
Cancer risk
Contradictory data — some models suggest pro-proliferative effects
—
CNS / Neurological
Insomnia, headache (anecdotal reports)
—
GI symptoms
Nausea, stomach discomfort (reported)
—
Antibody formation
No data (no long-term human trials)
Not reported; dipeptides generally low immunogenicity
Pregnancy / OB
Avoid — insufficient safety data
—
Evidence quality
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
—
Human safety data
—
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
MOTS-c
Vilon
1. Reconstitution
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Injection site
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Needle
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
—
06Stack Synergy
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation